Vonoprazan: A New Treatment Option for Acid-related Diseases
Keywords:
acid-related diseases, antisecretory drugs, vonoprazan, potassium competitive acid blockerAbstract
Acid-related disease is a common, public health problem that interferes with the livelihoods of patients. The most effective and re–commended drugs to inhibit acid secretion in the current guideline are proton pump inhibitors. It is later found to be less effective as well as to have other limitations such as gastric acid-lability, inhibition of H+/K+-ATPase enzyme only in stimulated state, and variable effects in patients with genetic differences. They are also unable to control symptoms during the night. In addition, long-term side effects such as reduction of the absorption of vitamin B12 and magnesium are observed. Therefore, efforts have been made to develop anti-acid secretion drugs to reduce these limitations. The most recent class of acid secretion inhibitors is the potassium competitive acid blocker, vonoprazan. The drug has advantages of rapid and long-acting. It is gastric acid-resistant. Food does not interfere with drug absorption, and drug can control nighttime symptoms. It is thus a new alternative for the treatment of acid-related diseases. However, long term study awaits investigation.
References
Sugano K. Vonoprazan fumarate, a novel potas–sium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clini–cal evidence to date. Ther Adv Gastroenterol. 2018;11:1-14.
Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334-40.
Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharm Ther 2018;168:12-22.
Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci. 2018; 63(2):302-11.
Rawia P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers- are they the next generation of proton pump inhibitors? World J Gastrointest Pharmoco Ther. 2018;9(7):63-8.
Mori H, Suzuki H. Role of acid suppression in acid–related diseases: proton pump inhibitor and potassium-competitive acid blockers. J Neurogastroenterol Motil. 2019;25(1):6-14.
Scott DR, Marcus Ea, Sachs G. Vonoprazan: marked competition for PPIs? Dig Dis Sci. 2016; 61(7):1783-4.
Jenkins H, Sakurai Y, Nishimura A. Randomised cli–nical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–48.
Sakurai Y, Shiino M, Horii S. Pharmacokinetic drug–drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a Phase 2, open-label, study in healthy Japanese men. Clin Drug Invest. 2017;37:39–49.
Kagami T, Sahara S, Ichikawa H. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016; 43:1048–59.
Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016; 55:409–18.
Wei-min Kong, Bin-bin Sun, Zhong-jian Wang, Xiao-ke Zheng, Kai-jing Zhao, Yang Che, et al. Physiologically based pharmacokinetic–pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. Acta Pharmacologica Sinica. 2020; 41:852–65.
Wang Y, Changxiong W, Shuanghu W, Quan Z, Dapeng D, Jihua S, et al. Cytochrome P450-based drug-drug interactions of vonoprazan in vitro and in vivo. Front Pharmacol. 2020;11(53):1-9.
Ashida K, Sakurai Y, Nishimura A. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–95.
Ashida K, Sakurai Y, Hori T. Randomised clinical trial: vonoprazan, a novel potassium competitive acid blocker vs lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240–51.
Hanada Y, Hoshino S, Hoshikawa Y. Su1120 efficacy of vonoprazan on PPI-resistant reflux esophagitis [Abstract]. Gastroenterology. 2016;150:S475.
Tabuchi M, Minami H, Akazawa Y, Ashida M. Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease. Biomedical report. 2021;14:25.
Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Miura Y, Lefor AK. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease. Kaohiung J Med Sci. 2017;33:616-22.
Iwakiri K, Umegaki E, Hiramatsu N. Su1119 a phase 3, randomized, double-blind, multicenter study to evaluate the dose-response relationships of acid-inhibitory effect of vonoprazan (20 mg, 40 mg) in patients with proton pump inhibitor-resistant erosive esophagitis [Abstract]. Gastroenterology. 2016;150:S475.
Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp. 2016;81:1-7.
Niikura R, Yamada A, Hirata Y, Hayakawa Y, Takahashi A, Shinozaki T. Efficacy of vonoprazan for gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Intern Med. 2018;57:2443-50.
Koike T, Saito M, Kikuchi H, Norita K, Kanno T and Hatta W. Vonoprazan reduces the GERD symptoms in the symptom index positive PPI-refractory NERD. J Gastroenterol Hepatol. 2016;31:21.
Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45:240-52.
Marabotto E, Ziola S, Savarino V. Vonoprazan fumarate for the treatment of gastric ulcers: a short review on emerging data clinical and experimental gastroenterology 2020;13:99–104.
Mizokami Y, Oda K, Funao N. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018;67(6):1042-51.
Kawai T, Oda K, Funao O. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018;67(6):1033–41.
Sugimoto M, Furuta T, Shirai N. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007;12(4):317–23.
Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949–56.
Shinozaki S, Nomoto H, Kondo Y. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci. 2016;32:255–260.
Shichijo S, Hirata Y, Niikura R. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis. 2016;17:670–5.
Noda H, Noguchi S, Yoshimine T. A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis. 2016;25:283–8.
Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106–14.
Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a phase 1, open-label, randomized, crossover study. Adv Ther. 2016;33:1519–35.
Miftahussurur M, Putra BP, Yamaoka Y. The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals. 2020;13:276-89.
Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consis–ting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017;22:DOI: 10.1111/hel.12374.
Sugimoto M, Yamaoka Y. Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Front Pharmacol. 2019;9:1-15.
Graham DY. Update on the use of vonoprazan: a competitive acid blocker. Gastro. 2018;154:462-6.
Kambara H, Hosohata K, Nakatsuji T, Ueno S, Oyama S, Inada A, et al. Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study. Pharmazie. 2020;75:527-30.
Downloads
Published
How to Cite
Issue
Section
License
ข้อความภายในบทความที่ตีพิมพ์ในวารสารเภสัชกรรมโรงพยาบาลทั้งหมด รวมถึงรูปภาพประกอบ ตาราง เป็นลิขสิทธิ์ของสมาคมเภสัชกรรมโรงพยาบาล (ประเทศไทย) การนำเนื้อหา ข้อความหรือข้อคิดเห็น รูปภาพ ตาราง ของบทความไปจัดพิมพ์เผยแพร่ในรูปแบบต่าง ๆ เพื่อใช้ประโยชน์ในเชิงพาณิชย์ ต้องได้รับอนุญาตจากกองบรรณาธิการวารสาร (สมาคมเภสัชกรรมโรงพยาบาล (ประเทศไทย)) อย่างเป็นลายลักษณ์อักษร
สมาคมเภสัชกรรมโรงพยาบาล (ประเทศไทย) อนุญาตให้สามารถนำไฟล์บทความไปใช้ประโยชน์และเผยแพร่ต่อได้ โดยอยู่ภายใต้เงื่อนไขสัญญาอนุญาตครีเอทีฟคอมมอน (Creative Commons License: CC) โดย ต้องแสดงที่มาจากวารสาร – ไม่ใช้เพื่อการค้า – ห้ามแก้ไขดัดแปลง, Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
ข้อความที่ปรากฏในบทความในวารสารเป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับสมาคมเภสัชกรรมโรงพยาบาล (ประเทศไทย) และบุคลากรในสมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใด ๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเอง ตลอดจนความรับผิดชอบด้านเนื้อหาและการตรวจร่างบทความเป็นของผู้เขียน ไม่เกี่ยวข้องกับกองบรรณาธิการ
.png){kind=spacer}
